DE2611690A1
(de)
*
|
1976-03-19 |
1977-09-22 |
Goedecke Ag |
Cyclische sulfonyloxyimide
|
JPS5776189U
(OSRAM)
*
|
1980-10-28 |
1982-05-11 |
|
|
JPS6152583U
(OSRAM)
*
|
1984-09-11 |
1986-04-09 |
|
|
JPS61139881U
(OSRAM)
*
|
1985-02-21 |
1986-08-29 |
|
|
US4876279A
(en)
*
|
1986-05-05 |
1989-10-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4960931A
(en)
*
|
1988-05-02 |
1990-10-02 |
Warner-Lambert Company |
Gabapentin mohohydrate and a process for producing the same
|
US4894476A
(en)
*
|
1988-05-02 |
1990-01-16 |
Warner-Lambert Company |
Gabapentin monohydrate and a process for producing the same
|
YU162789A
(en)
*
|
1988-09-01 |
1990-12-31 |
Lonza Ag |
2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
|
US5132451A
(en)
*
|
1989-08-25 |
1992-07-21 |
Warner-Lambert Company |
Process for cyclic amino acid anticonvulsant compounds
|
US5319135A
(en)
*
|
1989-08-25 |
1994-06-07 |
Warner-Lambert Company |
Process for cyclic amino acid anticonvulsant compounds
|
DE3928182A1
(de)
*
|
1989-08-25 |
1991-02-28 |
Goedecke Ag |
Verfahren zur herstellung von gabapentin
|
DE3928183A1
(de)
*
|
1989-08-25 |
1991-02-28 |
Goedecke Ag |
Lactamfreie cyclische aminosaeuren
|
FI107914B
(fi)
*
|
1989-08-25 |
2001-10-31 |
Warner Lambert Co |
Parannettu menetelmä syklisten aminohappoyhdisteiden valmistamiseksi ja menetelmässä käytettävä välituote
|
DE3928184A1
(de)
*
|
1989-08-25 |
1991-02-28 |
Goedecke Ag |
Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
|
US5157138A
(en)
*
|
1989-11-16 |
1992-10-20 |
Pfizer, Inc. |
Glutaric acid derivatives and preparation thereof
|
FI905584A7
(fi)
*
|
1989-11-16 |
1991-05-17 |
Lonza Ag |
Menetelmä 1-(aminometyyli)sykloheksaanietikkahapon valmistamiseksi
|
GB8925933D0
(en)
*
|
1989-11-16 |
1990-01-04 |
Pfizer Ltd |
Glutaric acid derivatives and preparation thereof
|
US5136091A
(en)
*
|
1989-11-16 |
1992-08-04 |
Lonza Ltd. |
Process for the production of 1-(aminomethyl) cyclohexane acetic acid
|
US5149870A
(en)
*
|
1989-11-16 |
1992-09-22 |
Lonza Ltd. |
Process for the production of 1-(aminomethyl)cyclohexane acetic acid
|
US5260467A
(en)
*
|
1989-11-16 |
1993-11-09 |
Pfizer Inc. |
Glutaric acid derivatives and preparation thereof
|
US5084479A
(en)
*
|
1990-01-02 |
1992-01-28 |
Warner-Lambert Company |
Novel methods for treating neurodegenerative diseases
|
US5025035A
(en)
*
|
1990-10-12 |
1991-06-18 |
Warner-Lambert Company |
Method of treating depression
|
US5792796A
(en)
*
|
1994-07-27 |
1998-08-11 |
Warner-Lambert Company |
Methods for treating anxiety and panic
|
US5510381A
(en)
*
|
1995-05-15 |
1996-04-23 |
Warner-Lambert Company |
Method of treatment of mania and bipolar disorder
|
JP2000511877A
(ja)
*
|
1996-02-07 |
2000-09-12 |
ワーナー―ランバート・コンパニー |
医薬としての新規な環状アミノ酸
|
SK283295B6
(sk)
*
|
1996-03-14 |
2003-05-02 |
Warner-Lambert Company |
Substituovaná cyklická aminokyselina, jej použitie a farmaceutický prostriedok na jej báze
|
EP0888285B1
(en)
*
|
1996-03-14 |
2001-12-12 |
Warner-Lambert Company |
Novel bridged cyclic amino acids as pharmaceutical agents
|
WO1998003167A1
(en)
|
1996-07-24 |
1998-01-29 |
Warner-Lambert Company |
Isobutylgaba and its derivatives for the treatment of pain
|
EP0937032B1
(en)
*
|
1996-10-23 |
2007-05-09 |
Warner-Lambert Company LLC |
Substituted gamma aminobutyric acids as pharmaceutical agents
|
IL119890A
(en)
*
|
1996-12-24 |
2002-03-10 |
Teva Pharma |
Gabapentin form iii and preparation of gabapentin form ii
|
US6255526B1
(en)
|
1996-12-24 |
2001-07-03 |
Teva Pharmaceutical Industries Ltd. |
Preparation of gabapentin
|
HRP980342A2
(en)
*
|
1997-06-25 |
1999-02-28 |
Warner Lambert Co |
Anti-inflammatory method
|
US6329429B1
(en)
|
1997-06-25 |
2001-12-11 |
Warner-Lambert Company |
Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
|
AU9019198A
(en)
|
1997-08-19 |
1999-03-08 |
Warner-Lambert Company |
Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
|
ATE311867T1
(de)
*
|
1997-09-08 |
2005-12-15 |
Warner Lambert Co |
Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
|
AU9318398A
(en)
|
1997-10-07 |
1999-04-27 |
Warner-Lambert Company |
Process for preparing a cyclic amino acid anticonvulsant compound
|
JP3756761B2
(ja)
*
|
1997-10-27 |
2006-03-15 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
医薬として有用な環状アミノ酸およびその誘導体
|
US6984659B2
(en)
*
|
1997-11-18 |
2006-01-10 |
Klinikum Der Albert-Ludwigs Universitaet |
2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
|
PL341231A1
(en)
|
1997-12-16 |
2001-03-26 |
Warner Lambert Co |
4(3)-substitute derivatives of 4(3)aminomethyl(thio)pyrane or piperidine derivatives (analogues of garbapentin), their production and application in treating neurological disorders
|
SI1047678T1
(en)
|
1997-12-16 |
2005-02-28 |
Warner-Lambert Company Llc |
1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
|
DK1045839T3
(da)
|
1997-12-16 |
2004-07-05 |
Warner Lambert Co |
Hidtil ukendte aminer som farmaceutiske midler
|
CA2309354A1
(en)
*
|
1998-01-23 |
1999-07-29 |
Leslie Magnus-Miller |
Gabapentin and its derivatives for the treatment of muscular and skeletal pain
|
EP0974351A3
(en)
*
|
1998-04-24 |
2000-12-13 |
Jouveinal |
Medicament for preventing and treating gastrointestinal damage
|
BR9910494B1
(pt)
*
|
1998-05-15 |
2011-11-01 |
|
composições sólidas contendo derivados de ácido gama-aminobutìrico e processo para o seu preparo.
|
US7309719B1
(en)
|
1998-05-15 |
2007-12-18 |
Warner Lambert Company, Llc |
Stabilized pharmaceutical preparation of gamma-aminobutyric acid derivatives and process for preparing the same
|
ES2137137B1
(es)
*
|
1998-05-25 |
2000-08-16 |
Medichem Sa |
Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
|
WO1999061424A1
(en)
|
1998-05-26 |
1999-12-02 |
Warner-Lambert Company |
Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
|
ITMI981535A1
(it)
*
|
1998-07-03 |
2000-01-03 |
Zambon Spa |
Processo per la preparazione di gabapentina
|
US20030045500A1
(en)
*
|
1998-07-09 |
2003-03-06 |
Leslie Magnus |
Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
|
FR2781793B1
(fr)
|
1998-08-03 |
2001-07-20 |
Prographarm Lab |
Procede de fabrication de granules de gabapentine enrobes
|
HU225502B1
(en)
*
|
1998-12-29 |
2007-01-29 |
Richter Gedeon Vegyeszet |
Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
|
IT1311984B1
(it)
*
|
1999-03-26 |
2002-03-22 |
Bioindustria Lab Italiano Medi |
Procedimento per la preparzione di gabapentin.
|
AU4334900A
(en)
*
|
1999-04-09 |
2000-11-14 |
Euro-Celtique S.A. |
Sodium channel blocker compositions and the use thereof
|
US6710190B1
(en)
|
1999-05-28 |
2004-03-23 |
Warner-Lambert Company |
3-heteroarylalkyl substituted gaba analogs
|
CA2371089A1
(en)
*
|
1999-05-28 |
2000-12-07 |
Warner-Lambert Company |
3-heteroarylalkyl substituted gaba analogs
|
US20080207755A1
(en)
*
|
2000-05-31 |
2008-08-28 |
Pfizer Inc |
Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
|
US7164034B2
(en)
*
|
1999-06-10 |
2007-01-16 |
Pfizer Inc. |
Alpha2delta ligands for fibromyalgia and other disorders
|
AP1397A
(en)
*
|
1999-06-10 |
2005-04-19 |
Warner Lambert Co |
Mono-and disubstituted 3-propyl gamma-aminobutyric acids.
|
US6294198B1
(en)
*
|
1999-08-24 |
2001-09-25 |
Purepac Pharmaceutical Co. |
Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
|
HN2000000224A
(es)
*
|
1999-10-20 |
2001-04-11 |
Warner Lambert Co |
Aminoacidos biciclicos como agentes farmaceuticos
|
GB2362646A
(en)
*
|
2000-05-26 |
2001-11-28 |
Warner Lambert Co |
Cyclic amino acid derivatives useful as pharmaceutical agents
|
DE1289364T1
(de)
|
2000-06-16 |
2003-09-18 |
Teva Pharmaceutical Industries Ltd., Petah Tiqva |
Stabiles gabapentin, das mehr als 20 ppm chlor enthält
|
WO2001097782A1
(en)
*
|
2000-06-16 |
2001-12-27 |
Teva Pharmaceutical Industries, Ltd. |
Stable gabapentin having ph within a controlled range
|
EP1384473A1
(en)
*
|
2000-06-16 |
2004-01-28 |
Teva Pharmaceutical Industries Ltd. |
Stable gabapentin containing more than 20 ppm of chlorine ion
|
EP1296671B1
(en)
*
|
2000-06-26 |
2008-03-26 |
Warner-Lambert Company LLC |
Gabapentin analogues for sleep disorders
|
GB2364049A
(en)
*
|
2000-06-28 |
2002-01-16 |
Warner Lambert Co |
Cyclic ketones and their use in the synthesis of amino acids
|
WO2002022568A1
(de)
*
|
2000-09-14 |
2002-03-21 |
Grünenthal GmbH |
β-THIO-AMINOSÄUREN
|
EP1343805A4
(en)
*
|
2000-10-06 |
2005-07-20 |
Xenoport Inc |
COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION
|
AU2002230398A1
(en)
*
|
2000-10-06 |
2002-04-29 |
Xenoport, Inc. |
Bile-acid conjugates for providing sustained systemic concentrations of drugs
|
US6620829B2
(en)
*
|
2000-10-17 |
2003-09-16 |
Warner-Lambert Company |
Method of treating noninflammatory cartilage damage
|
IT1319234B1
(it)
*
|
2000-10-23 |
2003-09-26 |
Zambon Spa |
Processo di preparazione di gabapentina.
|
GB2368579A
(en)
*
|
2000-10-31 |
2002-05-08 |
Parke Davis & Co Ltd |
Azole pharmaceutical agents
|
MXPA03003899A
(es)
*
|
2000-11-02 |
2005-02-17 |
Teva Pharma |
Proceso mejorado para la produccion de intermedio de gabapentina.
|
CA2430309A1
(en)
*
|
2000-11-30 |
2002-06-06 |
Pfizer Products Inc. |
Combination of gaba agonists and aldose reductase inhibitors
|
DE60106968T2
(de)
*
|
2000-11-30 |
2005-11-03 |
Pfizer Products Inc., Groton |
Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren
|
IT1319674B1
(it)
*
|
2000-12-01 |
2003-10-23 |
Erregierre Spa |
Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
|
WO2002074727A1
(en)
*
|
2001-03-16 |
2002-09-26 |
Solchem Italiana S.P.A. |
A process for the preparation of cyclic amino acids
|
ITMI20011132A1
(it)
|
2001-05-29 |
2002-11-29 |
Procos Spa |
Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
|
US7186855B2
(en)
*
|
2001-06-11 |
2007-03-06 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
IL159299A0
(en)
*
|
2001-06-11 |
2004-06-01 |
Xenoport Inc |
Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US7232924B2
(en)
*
|
2001-06-11 |
2007-06-19 |
Xenoport, Inc. |
Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
|
JP2005501013A
(ja)
*
|
2001-06-11 |
2005-01-13 |
ゼノポート,インコーポレイテッド |
Gaba類似体の全身濃度が持続するアミノ酸コンジュゲート
|
US8048917B2
(en)
*
|
2005-04-06 |
2011-11-01 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
IL144066A0
(en)
*
|
2001-06-28 |
2002-04-21 |
Bromine Compounds Ltd |
Process for the preparation of 1,1-cyclohexane diacetic monoamide
|
ITMI20011772A1
(it)
|
2001-08-10 |
2003-02-10 |
A M S A Anonima Materie Sint E |
Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
|
SI1423168T1
(sl)
*
|
2001-09-03 |
2006-06-30 |
Newron Pharm Spa |
Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba
|
US6800782B2
(en)
*
|
2001-10-09 |
2004-10-05 |
Warner-Lambert Co. |
Anhydrous crystalline forms of gabapentin
|
US20060159743A1
(en)
*
|
2001-10-25 |
2006-07-20 |
Depomed, Inc. |
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
|
US20070184104A1
(en)
*
|
2001-10-25 |
2007-08-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
US20030119908A1
(en)
*
|
2001-12-21 |
2003-06-26 |
Zambon Group S.P.A. |
Stable gabapentin compositions
|
ITMI20012750A1
(it)
|
2001-12-21 |
2003-06-21 |
Procos Spa |
Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
|
AU2003201716B2
(en)
*
|
2002-01-31 |
2008-04-17 |
Warner-Lambert Company Llc |
Alpha 2 delta ligands to treat tinnitus
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
US6927036B2
(en)
|
2002-02-19 |
2005-08-09 |
Xero Port, Inc. |
Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
|
AU2003222033A1
(en)
*
|
2002-03-20 |
2003-10-08 |
Xenoport |
Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
|
AU2003262383A1
(en)
*
|
2002-04-16 |
2003-11-03 |
Taro Pharmaceutical Industries Ltd. |
Process for preparing gabapentin
|
EP1549323A2
(en)
*
|
2002-05-07 |
2005-07-06 |
A & D Bioscience, Inc. |
Conjugates comprising central nervous system active drug
|
AU2003243180A1
(en)
*
|
2002-05-17 |
2003-12-12 |
Xenoport, Inc. |
Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
|
EP1515709A2
(en)
*
|
2002-06-27 |
2005-03-23 |
Warner-Lambert Company LLC |
Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder
|
CA2395931A1
(en)
*
|
2002-08-07 |
2004-02-07 |
Bernard Charles Sherman |
Solid compositions comprising gabapentin having improved stability
|
US7053122B2
(en)
*
|
2002-08-09 |
2006-05-30 |
Pfizer Inc |
Therapeutic use of aryl amino acid derivatives
|
US20040092522A1
(en)
*
|
2002-08-15 |
2004-05-13 |
Field Mark John |
Synergistic combinations
|
US20040092591A1
(en)
*
|
2002-08-15 |
2004-05-13 |
Blakemore David Clive |
Therapeutic use of fused bicyclic or tricyclic amino acids
|
US7419981B2
(en)
*
|
2002-08-15 |
2008-09-02 |
Pfizer Inc. |
Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
|
US20040092498A1
(en)
*
|
2002-08-16 |
2004-05-13 |
David Blakemore |
Substituted glycine derivatives for use as medicaments
|
ITMI20022071A1
(it)
*
|
2002-10-01 |
2004-04-02 |
Erregierre Spa |
Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato.
|
US7659305B2
(en)
*
|
2002-10-31 |
2010-02-09 |
Pfizer Inc. |
Therapeutic proline derivatives
|
AU2002356424A1
(en)
*
|
2002-11-18 |
2004-06-15 |
Nicholas Piramal India Limited |
Improved process for preparation of gabapentin
|
WO2004046108A1
(en)
*
|
2002-11-20 |
2004-06-03 |
Hikal Ltd. |
An improved process for the preparation of gabalactam
|
AU2003297909A1
(en)
*
|
2002-12-11 |
2004-06-30 |
Xenoport, Inc. |
Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
|
AU2003297927A1
(en)
*
|
2002-12-11 |
2004-06-30 |
Xenoport, Inc. |
Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
|
PL377662A1
(pl)
*
|
2002-12-13 |
2006-02-06 |
Warner-Lambert Company Llc |
Pregabalina i jej pochodne w leczeniu fibromialgii i innych zaburzeń pokrewnych
|
CA2451267A1
(en)
*
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
BR0316751A
(pt)
*
|
2002-12-13 |
2005-10-25 |
Warner Lambert Co |
Análogos de gabapentina para fibromialgia e outros distúrbios relacionados
|
US20040180958A1
(en)
*
|
2002-12-13 |
2004-09-16 |
Taylor Charles Price |
Method of treatment
|
DK1572173T3
(da)
|
2002-12-13 |
2010-06-14 |
Warner Lambert Co |
Alpha-2-delta-ligand til behandling af symptomer i den nedre urinvej
|
CN101862317A
(zh)
*
|
2002-12-13 |
2010-10-20 |
沃尼尔·朗伯有限责任公司 |
用于治疗纤维肌痛和其它疾病的普加巴林衍生物
|
GB0301143D0
(en)
*
|
2003-01-17 |
2003-02-19 |
Amedis Pharm Ltd |
Compounds and their use
|
PL377937A1
(pl)
*
|
2003-01-22 |
2006-02-20 |
Warner-Lambert Company Llc |
Pochodne cyklopropylo-beta-aminokwasu
|
BRPI0408110A
(pt)
*
|
2003-03-07 |
2006-03-01 |
Warner Lambert Co |
derivados de beta-aminoácido substituìdos com tetrazol e oxadiazolona
|
EP1622603A4
(en)
*
|
2003-03-25 |
2010-03-24 |
Kiel Lab Inc |
GABAPENTINIC PHENOLIC ACID SALTS IN SOLID DOSAGE FORMS AND METHODS OF USE
|
EP1628656B1
(en)
*
|
2003-03-25 |
2008-10-15 |
Kiel Laboratories, Inc. |
Gabapentin tannate in liquid and/or semi-solid dosage forms
|
WO2004093866A1
(en)
*
|
2003-03-25 |
2004-11-04 |
Kiel Laboratories, Inc. |
Process for preparing phenolic acid salts of gabapentin
|
CA2520468A1
(en)
*
|
2003-03-31 |
2004-10-21 |
Xenoport, Inc. |
Treating or preventing hot flashes using prodrugs of gaba analogs
|
US20040214893A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Matthew Peterson |
Gabapentin compositions
|
ITMI20030825A1
(it)
*
|
2003-04-18 |
2004-10-19 |
Farchemia Srl |
Procedimento per la preparazione di gabapentin esente da
|
US7439387B2
(en)
*
|
2003-04-21 |
2008-10-21 |
Matrix Laboratories Ltd. |
Process for the preparation of Gabapentin form-II
|
CA2525366A1
(en)
*
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
|
CA2528388A1
(en)
*
|
2003-06-19 |
2004-12-23 |
Pfizer Products Inc. |
Biocatalytic preparation of 1-cyanocyclohexaneacetic acid
|
US7169812B2
(en)
*
|
2003-07-01 |
2007-01-30 |
Medtronic, Inc. |
Process for producing injectable gabapentin compositions
|
WO2005002585A1
(en)
*
|
2003-07-02 |
2005-01-13 |
Warner-Lambert Company Llc |
Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
|
US20050013863A1
(en)
*
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
WO2005046566A2
(en)
*
|
2003-08-04 |
2005-05-26 |
Sun Pharmaceutical Industries Limited |
Stable gabapentin containing composition
|
US20050043407A1
(en)
*
|
2003-08-22 |
2005-02-24 |
Pfizer Inc |
Pharmaceutical composition for the prevention and treatment of addiction in a mammal
|
AU2004272111A1
(en)
*
|
2003-09-11 |
2005-03-24 |
Xenoport, Inc. |
Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
|
EP1663398B1
(en)
|
2003-09-12 |
2009-11-25 |
Pfizer Limited |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
|
KR20060087560A
(ko)
*
|
2003-09-12 |
2006-08-02 |
워너-램버트 캄파니 엘엘씨 |
알파-2-델타 리간드 및 ssri 및/또는 snri를포함하는 우울증 및 불안 장애 치료용 조합물
|
BRPI0414481A
(pt)
*
|
2003-09-17 |
2006-11-14 |
Xenoport Inc |
métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
|
NZ546381A
(en)
*
|
2003-10-14 |
2010-01-29 |
Xenoport Inc |
Crystalline form of gamma-aminobutyric acid analog
|
ITMI20032165A1
(it)
*
|
2003-11-11 |
2005-05-12 |
Zambon Spa |
Processo di preparazione di gabapentina
|
DK1691811T3
(da)
|
2003-12-11 |
2014-10-20 |
Sunovion Pharmaceuticals Inc |
Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
|
JP2007537151A
(ja)
*
|
2004-01-29 |
2007-12-20 |
ファイザー・プロダクツ・インク |
γ−アミノ酪酸モジュレータと5−HT1B受容体アンタゴニストとの組合せ
|
US20050187295A1
(en)
*
|
2004-02-19 |
2005-08-25 |
Surendra Kalyan |
Processes for the preparation of gabapentin
|
EP1763503A1
(en)
*
|
2004-03-17 |
2007-03-21 |
Hikal Limited |
4-t-butylgabapentin and its synthesis
|
ITMI20040579A1
(it)
*
|
2004-03-25 |
2004-06-25 |
Zambon Spa |
Processo di preparazione di gabapentina
|
US20050233010A1
(en)
*
|
2004-04-19 |
2005-10-20 |
Satow Philip M |
Lithium combinations, and uses related thereto
|
BRPI0511941A
(pt)
*
|
2004-06-09 |
2008-01-22 |
Pfizer |
uso de (s, s)-reboxetina ou reboxetina racêmica
|
GB0416228D0
(en)
*
|
2004-07-20 |
2004-08-25 |
Sandoz Ind Products S A |
Process for the preparation of gabapentin
|
GB0419849D0
(en)
*
|
2004-09-07 |
2004-10-13 |
Pfizer Ltd |
Pharmaceutical combination
|
CA2577408C
(en)
*
|
2004-09-10 |
2013-07-09 |
Elena Barbanti |
Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators
|
US8795725B2
(en)
|
2004-11-04 |
2014-08-05 |
Xenoport, Inc. |
GABA analog prodrug sustained release oral dosage forms
|
EP2258357A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
US7678363B2
(en)
|
2005-08-26 |
2010-03-16 |
Braincells Inc |
Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
|
BRPI0616402A2
(pt)
*
|
2005-09-23 |
2011-06-21 |
Janssen Pharmaceutica Nv |
moduladores de canabinóide de hexaidro-cicloeptapirazol
|
WO2007035945A1
(en)
|
2005-09-23 |
2007-03-29 |
Janssen Pharmaceutica, N.V. |
Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
|
US8378096B2
(en)
*
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
US7825151B2
(en)
*
|
2005-09-23 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Hexahydro-cyclooctyl pyrazole cannabinoid modulators
|
US8378117B2
(en)
*
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
EP1931335B1
(en)
*
|
2005-09-23 |
2010-02-24 |
Janssen Pharmaceutica N.V. |
Hexahydro cyclooctyl pyrazole cannabinoid modulators
|
US7985756B2
(en)
|
2005-10-21 |
2011-07-26 |
Braincells Inc. |
Modulation of neurogenesis by PDE inhibition
|
EP2314289A1
(en)
|
2005-10-31 |
2011-04-27 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
US20070117858A1
(en)
*
|
2005-11-23 |
2007-05-24 |
Mingde Xia |
Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
|
US20090176882A1
(en)
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
US7526911B2
(en)
*
|
2006-02-03 |
2009-05-05 |
Rolls-Royce Corporation |
Gas turbine engine fuel system with fuel metering valve
|
EP1820502A1
(en)
|
2006-02-10 |
2007-08-22 |
Laboratorios Del Dr. Esteve, S.A. |
Active substance combination comprising azolylcarbinol compounds
|
WO2007095513A1
(en)
*
|
2006-02-14 |
2007-08-23 |
Janssen Pharmaceutica, Nv |
Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators
|
RU2008135907A
(ru)
*
|
2006-03-06 |
2010-04-20 |
Пфайзер Продактс Инк. (Us) |
Альфа-2-дельта лиганды для невосстановительного сна
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US8012957B2
(en)
*
|
2006-03-27 |
2011-09-06 |
Janssen Pharmaceutica Nv |
Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
|
US20070254911A1
(en)
*
|
2006-03-27 |
2007-11-01 |
Mingde Xia |
Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
|
JP2009536669A
(ja)
|
2006-05-09 |
2009-10-15 |
ブレインセルス,インコーポレイティド |
アンジオテンシン調節による神経新生
|
CA2651862A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
US7442834B2
(en)
*
|
2006-06-12 |
2008-10-28 |
Zhejiang Chiral Medicine Chemicals Co., Ltd. |
Process suitable for industrial scale production of gabapentin
|
CN101484413B
(zh)
*
|
2006-06-30 |
2014-05-14 |
Zach系统股份公司 |
制备加巴喷丁的方法
|
BRPI0716604A2
(pt)
|
2006-09-08 |
2013-04-09 |
Braincells Inc |
combinaÇÕes contendo um derivado de 4-acilaminopiridina
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
MX2009006080A
(es)
*
|
2006-12-08 |
2009-07-14 |
Xenoport Inc |
Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.
|
EA017171B1
(ru)
|
2006-12-22 |
2012-10-30 |
Рекордати Айерленд Лимитед |
КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП)
|
WO2008111096A2
(en)
*
|
2007-03-15 |
2008-09-18 |
Sun Pharma Advanced Research Company Ltd |
Novel prodrugs
|
US20090041806A1
(en)
*
|
2007-06-15 |
2009-02-12 |
Xenoport, Inc. |
Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
|
US7943653B2
(en)
*
|
2007-08-13 |
2011-05-17 |
Janssen Pharmaceutica N.V. |
Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
|
US20090062392A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched gabapentin
|
TW200936123A
(en)
*
|
2007-11-06 |
2009-09-01 |
Xenoport Inc |
Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain
|
WO2009094563A2
(en)
|
2008-01-25 |
2009-07-30 |
Xenoport, Inc. |
Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
|
EP2250143B1
(en)
*
|
2008-01-25 |
2016-04-20 |
XenoPort, Inc. |
Method for the enzymatic kinetic resolution of acyloxyalkyl thiocarbonates used for the synthesis of acyloxyalkyl carbamates
|
US7868043B2
(en)
|
2008-01-25 |
2011-01-11 |
Xenoport, Inc. |
Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
|
EP2116539A1
(en)
|
2008-04-25 |
2009-11-11 |
Laboratorios Del. Dr. Esteve, S.A. |
1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
|
US20100190752A1
(en)
|
2008-09-05 |
2010-07-29 |
Gruenenthal Gmbh |
Pharmaceutical Combination
|
EP2344447B1
(en)
|
2008-10-08 |
2016-06-08 |
Xgene Pharmaceutical Inc |
Gaba conjugates and methods of use thereof
|
WO2010099200A1
(en)
|
2009-02-24 |
2010-09-02 |
Nektar Therapeutics |
Oligomer-amino acid conjugates
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US20110130454A1
(en)
*
|
2009-11-24 |
2011-06-02 |
Xenoport, Inc. |
Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
|
US20110124705A1
(en)
*
|
2009-11-24 |
2011-05-26 |
Xenoport, Inc. |
Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
|
JP5815552B2
(ja)
|
2009-12-08 |
2015-11-17 |
ケース ウェスタン リザーブ ユニバーシティCase Westernreserve University |
眼疾患を治療する化合物および方法
|
EP2353591A1
(en)
|
2010-02-04 |
2011-08-10 |
Laboratorios Del. Dr. Esteve, S.A. |
Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
|
EP2368872A1
(en)
|
2010-03-25 |
2011-09-28 |
Serichim S.r.l. |
Process for the preparation of Gabapentin
|
EP2388005A1
(en)
|
2010-05-21 |
2011-11-23 |
Laboratorios Del. Dr. Esteve, S.A. |
Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
|
WO2011151708A1
(en)
|
2010-06-01 |
2011-12-08 |
Rubicon Research Private Limited |
Gastroretentive dosage forms of gaba analogs
|
US8431739B2
(en)
|
2010-06-14 |
2013-04-30 |
Divi's Laboratories, Ltd. |
Process for the preparation of gabapentin
|
US8946267B2
(en)
|
2010-07-30 |
2015-02-03 |
Toray Industries, Inc. |
Therapeutic agent or prophylactic agent for neuropathic pain
|
EP2415471A1
(en)
|
2010-08-03 |
2012-02-08 |
Laboratorios Del. Dr. Esteve, S.A. |
Use of sigma ligands in opioid-induced hyperalgesia
|
JP2013216580A
(ja)
*
|
2010-08-06 |
2013-10-24 |
Kyorin Pharmaceutical Co Ltd |
ビシクロ[2.2.2]オクチルアミン誘導体の製造方法
|
EP2524694A1
(en)
|
2011-05-19 |
2012-11-21 |
Laboratorios Del. Dr. Esteve, S.A. |
Use of sigma ligands in diabetes type-2 associated pain
|
EP2530072A1
(en)
|
2011-06-03 |
2012-12-05 |
Lacer, S.A. |
New compounds, synthesis and use thereof in the treatment of pain
|
US9066853B2
(en)
|
2013-01-15 |
2015-06-30 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable fiber
|
ITMI20131757A1
(it)
|
2013-10-22 |
2015-04-23 |
Zach System Spa |
Processo di preparazione di gabapentina
|
DK3067430T3
(da)
|
2013-11-01 |
2020-09-21 |
Glytech Inc |
Fremgangsmåde til fremstilling af d-form-eller l-form-aminosyrederivat med en thiolgruppe
|
MA39146A1
(fr)
|
2013-12-17 |
2017-11-30 |
Esteve Labor Dr |
Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
|
KR20160097366A
(ko)
|
2013-12-17 |
2016-08-17 |
라보라토리오스 델 드라. 에스테브.에스.에이. |
세로토닌-노르에피네프린 재흡수 억제제들(SNRIs) 및 시그마 리셉터 리간드들 조합
|
WO2015144825A1
(en)
|
2014-03-27 |
2015-10-01 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Oral liquid pharmaceutical solution of gabapentin
|
ES2908641T3
(es)
|
2016-12-16 |
2022-05-03 |
Idorsia Pharmaceuticals Ltd |
Combinación farmacéutica que comprende un bloqueador del canal del calcio de tipo T
|
MX384760B
(es)
|
2018-07-04 |
2025-03-14 |
Federico Amezcua Amezcua |
Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
|
US10399926B1
(en)
|
2018-08-01 |
2019-09-03 |
Divi's Laboratories Ltd. |
Process for the preparation of gabapentin
|
CN112839661A
(zh)
|
2018-10-11 |
2021-05-25 |
萨尼菲特治疗有限公司 |
用于治疗异位钙化的肌醇磷酸酯类
|
AU2020370758B2
(en)
|
2019-10-25 |
2025-08-14 |
Kyoto University |
Preventative or therapeutic agent for tauopathy
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
GB2625579A
(en)
|
2022-12-21 |
2024-06-26 |
Novumgen Ltd |
An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same
|